NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JNJ

Johnson & Johnson

Jul 09 • 04:00PM ET

156.28

Dollar change +0.49
Percentage change 0.31	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM DGRO QUAL

Scroll to Statements

Index	DJIA, S&P 500	P/E	17.37	EPS (ttm)	9.00	Insider Own	0.14%	Shs Outstand	2.41B	Perf Week	0.23%
Market Cap	376.02B	Forward P/E	14.03	EPS next Y	11.14	Insider Trans	-0.60%	Shs Float	2.40B	Perf Month	0.81%
Enterprise Value	389.49B	PEG	2.91	EPS next Q	2.68	Inst Own	73.47%	Short Float	0.68%	Perf Quarter	3.76%
Income	21.81B	P/S	4.21	EPS this Y	6.51%	Inst Trans	0.81%	Short Ratio	1.96	Perf Half Y	8.38%
Sales	89.33B	P/B	4.81	EPS next Y	4.76%	ROA	11.93%	Short Interest	16.33M	Perf YTD	8.06%
Book/sh	32.47	P/C	9.70	EPS next 5Y	5.96%	ROE	29.45%	52W High	169.99 -8.07%	Perf Year	6.69%
Cash/sh	16.12	P/FCF	18.46	EPS past 3/5Y	-9.49% 0.55%	ROIC	18.73%	52W Low	140.68 11.09%	Perf 3Y	-12.95%
Dividend Est.	5.15 (3.30%)	EV/EBITDA	13.63	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.24%	Volatility	1.07% 1.34%	Perf 5Y	11.33%
Dividend TTM	5.02 (3.21%)	EV/Sales	4.36	EPS Y/Y TTM	29.21%	Oper. Margin	23.83%	ATR (14)	2.15	Perf 10Y	60.35%
Dividend Ex-Date	May 27, 2025	Quick Ratio	1.03	Sales Y/Y TTM	-0.37%	Profit Margin	24.41%	RSI (14)	58.21	Recom	2.20
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.26	EPS Q/Q	238.80%	SMA20	1.44%	Beta	0.39	Target Price	170.89
Payout	84.80%	Debt/Eq	0.67	Sales Q/Q	2.39%	SMA50	1.58%	Rel Volume	0.74	Prev Close	155.79
Employees	138100	LT Debt/Eq	0.49	Earnings	Jul 16 BMO	SMA200	0.60%	Avg Volume	8.35M	Price	156.28
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.33% 1.55%	Trades		Volume	6,139,698	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183

Show Previous Ratings

Today 01:45PM	Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade (Reuters)
11:41AM	Wall Street waves off Trump's 200% pharma tariff threat (Yahoo Finance)
10:00AM	Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:40AM	Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term (Zacks)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:11AM	Loading…
09:11AM	JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now? (Zacks)
08:40AM	SpaceX Just Made Elon Musk $20 Billion Richer (Barrons.com)
08:18AM	Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks (Zacks)
01:03AM	Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage (Insider Monkey)
Jul-08-25 08:27AM	How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results? (Zacks)
08:00AM	Supplemental new drug application submitted to U.S. FDA for CAPLYTA (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo (PR Newswire)
06:03AM	Analysis: 'Trump Effect' website takes credit for US investment made under Biden (Reuters)
Jul-07-25 09:50AM	Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock (Zacks)
09:30AM	Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales? (Zacks)
06:36AM	J&Js Abiomed recalls heart pump controllers after 3 patients die (MedTech Dive)
06:07AM	Loading…
06:07AM	Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead? (Motley Fool)
Jul-06-25 03:35AM	J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ) (Insider Monkey)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
04:19AM	North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE (GlobeNewswire)
03:22AM	Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds (Insider Monkey)
Jul-03-25 12:10PM	Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again (Zacks)
11:45AM	Johnson & Johnson (JNJ) Could Be a Great Choice (Zacks)
09:03AM	The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle (Zacks)
09:00AM	Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now? (Zacks)
08:41AM	Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations (GlobeNewswire)
08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
07:44AM	Regeneron nabs dosing edge with Lynozyfics FDA approval in multiple myeloma (Pharmaceutical Technology)
Jul-02-25 04:30PM	Top Analyst Reports for Johnson & Johnson, Home Depot and Micron (Zacks)
09:07AM	Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? (Zacks)
Jul-01-25 05:45PM	Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts (Zacks)
03:06PM	Loading…
03:06PM	A Promising Depression Drug Works. Psychedelics Are Back. (Barrons.com)
06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
06:20AM	Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? (Zacks)
06:20AM	Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar? (Zacks)
Jun-30-25 02:33PM	Wall Street Backs Los Angeles Wildfire Lawsuits, Chasing Billions (Bloomberg)
01:27PM	PJM Appoints Deena O'Brien as Senior Director of Communications (PR Newswire)
10:00AM	The Hackett Group® Announces Winners of the 2025 Hackett Innovation Awards (Business Wire)
07:00AM	Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
06:45AM	Vicarious Surgical Announces Election of New Directors (Business Wire)
Jun-27-25 05:38AM	Here's What to Expect From Johnson & Johnson's Next Earnings Report (Barchart)
04:12AM	Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
01:16AM	How PepsiCo, Johnson & Johnson, And Skyworks Solutions Can Put Cash In Your Pocket (Benzinga)
Jun-26-25 09:03PM	Why JNJ Is a Long-Term Winner (Insider Monkey)
09:40AM	J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025? (Zacks)
08:45AM	Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever (Motley Fool)
06:12AM	Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements (GlobeNewswire)
06:00AM	J&J teams with Nvidia, Amazon on fund for AI surgery solutions (MedTech Dive)
Jun-25-25 03:08PM	Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial (Insider Monkey)
04:29AM	Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US (Insider Monkey)
03:47AM	Johnson & Johnson MedTech Expands VOLT Platform With New Wrist, Upper Arm Fracture Systems (Insider Monkey)
Jun-24-25 01:06PM	Johnson & Johnson announces new data presented at EAN of IMAAVY (TipRanks)
12:20PM	MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
08:00AM	5 Dividend Stocks Poised to Profit From the AI Efficiency Boom (Motley Fool)
05:18AM	J&J introduces disposable contact lens for astigmatism and presbyopia (Medical Device Network)
03:39AM	How a Big Pharma veteran looks to stand out in biotech as a unique drug hunter (Pharma Voice)
Jun-23-25 02:31PM	Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing (Benzinga)
09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:22AM	J&J Adds More Than $15B in Six Months: How to Play JNJ Stock? (Zacks)
09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
08:00AM	Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM (PR Newswire)
07:32AM	IMAAVY (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) (PR Newswire)
05:05AM	Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson (Zacks)
Jun-21-25 02:01PM	Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' (Benzinga)
12:12AM	JNJ's Consistent Payout Makes It a Top Pick for Down Markets (Insider Monkey)
Jun-20-25 03:54PM	Don't Overlook Jabil (JBL) Stock After Topping Its Q3 Expectations (Zacks)
06:39AM	IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant (GlobeNewswire)
Jun-19-25 12:40PM	J&J MedTech introduces new plates for VOLT fracture management platform (Medical Device Network)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:08AM	Johnson & Johnson submits sBLA to FDA to extend use of ustekinumab (Pharmaceutical Business Review)
Jun-18-25 06:43PM	Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit (Business Wire)
10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
06:20AM	Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? (Zacks)
05:05AM	Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions (Medical Device Network)
05:02AM	2 Dividend Stocks to Buy and Never Sell (Motley Fool)
Jun-17-25 05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
12:11PM	Johnson & Johnson's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
09:37AM	ISRG's Minimally Invasive Ecosystem Powers Surgical Precision (Zacks)
06:20AM	Should WisdomTree U.S. LargeCap Dividend ETF (DLN) Be on Your Investing Radar? (Zacks)
06:20AM	Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? (Zacks)
Jun-16-25 05:45PM	Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know (Zacks)
09:00AM	Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE? (Zacks)
07:43AM	J&J reports results from antibody combo trial for MM patients (Clinical Trials Arena)
Jun-15-25 10:00AM	Pharma manufacturing 'boom' faces high costs, potential delays (Yahoo Finance)
05:33AM	Johnson & Johnson (JNJ) Announces Results for Phase 3b APEX Study (Insider Monkey)
03:15AM	Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease (PR Newswire)
Jun-13-25 09:30PM	UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times (Insider Monkey)
08:56PM	Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG) (TipRanks)
12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
11:30AM	JPMorgan biotech/pharma analysts hold analyst/industry conference call (TipRanks)
11:10AM	Johnson & Johnson announces new Phase 1b data on bleximenib (TipRanks)
11:00AM	Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma (PR Newswire)
08:19AM	BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth? (Zacks)
04:25AM	Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Stock Instead? (Motley Fool)
Jun-12-25 11:57AM	Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image (Barrons.com)
11:00AM	New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia (PR Newswire)
05:40AM	J&Js Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial (Clinical Trials Arena)
Jun-11-25 04:45PM	Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit (Insider Monkey)
10:57AM	Trump Wants Cheaper Drugs Like Europe Has. How It Works. (Barrons.com)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience